Northwestern University Stem Cell Therapy Clinic Closes Abruptly

A Chicago-based center that has long operated a clinical trial program for stem cell therapies, has stopped recruiting further patients as its chief, Richard Burt, leaves for a research sabbatical.

Written byKatarina Zimmer
| 5 min read
northwestern memorial hospital hsct hematopoietic stem cell clinical trial multiple sclerosis ms selma blair richard burt

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

ABOVE: FLICKR, STEVE RHODES

A pioneering stem cell clinical trial program in the US is closing up shop, a surprise move for what had appeared to be a successful endeavor at testing hematopoietic stem cell transplantations (HSCT) for autoimmune and other diseases. Northwestern Medicine’s immunotherapy and autoimmune diseases program, based at Northwestern Memorial Hospital in downtown Chicago, will no longer accept new patients for clinical trials, a spokesperson for Northwestern Memorial HealthCare confirmed this week (September 5).

The center specializes in conducting hematopoietic stem cell transplantations (HSCT), whereby stem cells are intravenously infused into a patient whose bone marrow or immune system is defective due to disease. The stem cells are obtained from a patient’s own bone marrow or peripheral blood, or that of another person. Patients are typically treated there as part of clinical studies testing the use of HSCT for autoimmune diseases, such as multiple sclerosis (MS), and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies